{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-179391","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.525737+00:00","generated_at":"2026-05-15T03:51:11.070332+00:00","sec_items":["3.01","3.03","5.03","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split","bullets":["Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.","Company must close at $1.00+ for at least 10 consecutive business days by May 15.","Reverse stock split at 1-for-35 effective April 30, 2026; trading continues on Nasdaq under JAGX.","Reverse split approved at April 20, 2026 special meeting; no fractional shares – cash in lieu.","Panel retains jurisdiction until September 1, 2026; delisting risk persists if compliance not met."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179391","json":"https://secwatch.observer/filing/0001193125-26-179391.json","markdown":"https://secwatch.observer/filing/0001193125-26-179391.md","text":"https://secwatch.observer/filing/0001193125-26-179391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:51:11.070332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29febf435701ff486c2894191b8f7bc8b79bc5f3","claim":"Jaguar Health, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).","evidence_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","confidence":0.9},{"claim_id":"1ed3755fda914724c8141d8f2429c576e283cbc6","claim":"Jaguar Health, Inc.: Filed Eleventh Amendment to Third Amended and Restated Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2026-04-30).","evidence_excerpt":"the Company filed the Eleventh Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-054565","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-11T21:09:36+00:00","headline":"AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal","event_type":"regulatory","sec_items":["3.01","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 5.03, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054565","json":"https://secwatch.observer/filing/0001213900-26-054565.json","markdown":"https://secwatch.observer/filing/0001213900-26-054565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/ea0290063-8k_allied.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"termination\nbefore an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company\nthat the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did\nnot comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant\nto Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during\na 180-day compliance period and is not eligible for a second 180-day complian","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm"}},{"accession":"0001731122-26-000682","ticker":"SDOT","company_name":"Sadot Group Inc.","filed_at":"2026-05-06T23:59:59+00:00","headline":"Nasdaq notifies Sadot Group of stockholders' equity deficiency; delisting risk","event_type":"regulatory","sec_items":["3.01","5.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice, governance_change","same SEC item: 3.01, 5.03, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000682","json":"https://secwatch.observer/filing/0001731122-26-000682.json","markdown":"https://secwatch.observer/filing/0001731122-26-000682.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/0001731122-26-000682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/e7614_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 5, 2026, Sadot Group Inc. (the “Company”)\nreceived a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company\nthat it no longer satisfies the minimum stockhold","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/0001731122-26-000682-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}},{"accession":"0001493152-26-025454","ticker":"GWAV","company_name":"Greenwave Technology Solutions, Inc.","filed_at":"2026-05-27T21:25:20+00:00","headline":"Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025454","json":"https://secwatch.observer/filing/0001493152-26-025454.json","markdown":"https://secwatch.observer/filing/0001493152-26-025454.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s\nfailure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm"}},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 22, 2026, Charlton\nAria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm"}},{"accession":"0001213900-26-061511","ticker":"BRLS","company_name":"Borealis Foods Inc.","filed_at":"2026-05-27T20:15:20+00:00","headline":"Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061511","json":"https://secwatch.observer/filing/0001213900-26-061511.json","markdown":"https://secwatch.observer/filing/0001213900-26-061511.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/ea0292244-8k_borealis.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","comparable_excerpt":"May 21, 2026, a notice\n(the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the\nCompany has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}